Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.48 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | RXRG | P48443 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777434 | 0.84 | FFAR4 (0.66) | FFAR4GABRA5TSHRGPBAR1MAPT | |
| SCHEMBL5775556 | 0.83 | MAPT (0.56) | FFAR4GABRA5GPBAR1MAPT | |
| SCHEMBL2301669 | 0.80 | FFAR4 (0.76) | FFAR4GABRA5 | |
| SCHEMBL2301689 | 0.80 | FFAR4 (1.00) | FFAR4 | |
| SCHEMBL2928713 | 0.79 | GABRA5 (0.52) | FFAR4GABRA5GPBAR1 | |
| SCHEMBL5774888 | 0.78 | CYP2C19 (0.58) | GPBAR1MAPTKMT2ARXRARXRB | |
| SCHEMBL5773713 | 0.77 | GABRA5 (0.50) | FFAR4GABRA5GPBAR1MAPT | |
| SCHEMBL5744413 | 0.75 | GABRA5 (0.49) | FFAR4GABRA5GPBAR1MEN1MAPT | |
| SCHEMBL3548012 | 0.75 | GPBAR1 (0.66) | GABRA5TSHRGPBAR1MEN1MAPT | |
| SCHEMBL5777101 | 0.74 | RXRA (0.54) | FFAR4GABRA5GPBAR1MAPTRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | FFAR4 143/4885GABRA5 707/4885TSHR 534/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | FFAR4 145/4885GABRA5 991/4885TSHR 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.